Sitemap > Breaking Research > Cardiovascular Disorders
Displaying 201 - 250 of 4862 results
- 4-Aryl-3-(mercapto)quinolin-2-ones: novel maxi-K channel opening relaxants of corporal smooth muscle.
- Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial.
- Synthetic curcumin analogs inhibit activator protein-1 transcription and tumor-induced angiogenesis.
- Induction of heme oxygenase-1 is involved in anti-proliferative effects of paclitaxel on rat vascular smooth muscle cells.
- The post-ischemic administration of 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e), a novel calmodulin antagonist, prevents delayed neuronal death in gerbil hippocampus.
- Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor.
- Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity.
- Renin-angiotensin blockade attenuates cardiac myofibrillar remodelling in chronic diabetes.
- Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects.
- Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
- Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms.
- Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
- Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial.
- Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries.
- Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
- Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
- Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery.
- Inhibition of matrix metalloproteinase activity by TIMP-1 gene transfer effectively treats ischemic cardiomyopathy.
- Suppression of graft coronary artery disease by a brief treatment with a selective epsilonPKC activator and a deltaPKC inhibitor in murine cardiac allografts.
- Overexpression of human copper/zinc superoxide dismutase (SOD1) suppresses ischemia-reperfusion injury and subsequent development of graft coronary artery disease in murine cardiac grafts.
- Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis.
- Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease.
- Use of beta-blockers and risk of fractures.
- Endoxin antagonist lessens myocardial ischemia reperfusion injury.
- Identification of a human heme exporter that is essential for erythropoiesis.
- JunD reduces tumor angiogenesis by protecting cells from oxidative stress.
- Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo.
- Regulation of HAX-1 anti-apoptotic protein by Omi/HtrA2 protease during cell death.
- VIAF, a conserved inhibitor of apoptosis (IAP)-interacting factor that modulates caspase activation.
- Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice.
- Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP.
- Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).
- Comparison of frequency of insulin resistance after coronary stenting in patients with type 2 diabetes mellitus with versus without coronary restenosis.
- Gene therapy for chronic myocardial ischemia using platelet-derived endothelial cell growth factor in dogs.
- Apolipoprotein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine complex (ETC-216) protects the in vivo rabbit heart from regional ischemia-reperfusion injury.
- cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling.
- Design, synthesis, and evaluation of oxyanion-hole selective inhibitor substituents for the S1 subsite of factor Xa.
- Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.
- Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial.
- Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors.
- Ximelagatran: an oral direct thrombin inhibitor.
- OX40 (CD134) blockade inhibits the co-stimulatory cascade and promotes heart allograft survival.
- Cardiovascular risk and COX-2 inhibition in rheumatological practice.
- Novel RGD-like molecules based on the tyrosine template: design, synthesis, and biological evaluation on isolated integrins alphaVbeta3/alphaIIbbeta3 and in cellular adhesion tests.
- Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives.
- E-selectin blockade decreases adventitial inflammation and attenuates intimal hyperplasia in rat carotid arteries after balloon injury.
- Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.
- Physiological levels of amyloid peptides stimulate the angiogenic response through FGF-2.
- The impact of DeltaG on the oral bioavailability of low bioavailable therapeutic agents.
- Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 Next >